On the afternoon of March 15, 2026, the Healthcare Industry Alumni Networking Session, hosted by the Peking University-Vlerick MBA 2023 part-time class（VP23） committee of Peking University's National School of Development (NSD), took place at the picturesque Chengze Garden on the NSD campus. Attorney Gao Yonghua, Partner at Global Law Office, was invited to lead an in-depth dialogue with attending alumni from the healthcare sector.

Cross-Border BD: Legal Compliance and Strategic Negotiation

Mr. Gao was joined by Ms. Lu Aixia, a VP23 Healthcare Group student at NSD, and special guest Dr. Qing Jing for a focused discussion on the legal and compliance challenges inherent in cross-border business development (BD) transactions. Dr. Qing Jing highlighted that China's R&D ecosystem has made substantial contributions to the global pharmaceutical pipeline through its hallmark approach of being "efficient, rapid, high-quality, and cost-effective." She expressed strong optimism regarding the future trajectory of China's innovative drug sector.

Drawing from her extensive practical experience, Ms. Lu Aixia shed light on the nuanced dynamics of negotiation and collaboration that ultimately drive successful overseas BD deals. She further illustrated this with a compelling case study, demonstrating how a skilled BD professional can strategically apply "reverse management" or "backward pressure" to prioritize transaction timelines and accelerate deal closure across all involved parties.

Round-Table Discussion: New Regulations and AI-Driven Discovery

The round-table segment featured special guest Ms. Wang Xiuping, VP23 student Mr. Gao Yongguo, and Attorney Gao Yonghua in a captivating exchange on the latest cell therapy regulations and the transformative impact of AI on drug discovery.

Ms. Wang offered valuable insights into the broader pharmaceutical industry implications stemming from Circulars No. 818 and No. 828. Meanwhile, Mr. Gao Yongguo leveraged his diverse professional background—spanning tenures at IBM, Oracle, AI-driven drug discovery firms, and CROs—to deliver a nuanced analysis of AI's profound influence on the industry. He also provided a candid comparison of the cultural and operational friction between the rapid-iteration "internet mindset" and the rigorous, long-cycle nature of traditional pharmaceutical R&D.

Q&A Session: Fostering Cross-Disciplinary Dialogue

Ms. Kou Renhua, a VP23 alumna of Peking University NSD, joined the panel on stage to field questions and share concluding remarks. The audience actively engaged the speakers on the pressing topics of innovative medicine and related legal complexities. The session served as a vibrant platform for the exchange of cutting-edge industry insights, facilitating robust dialogue among diverse perspectives in a lively and collaborative atmosphere.